BioSpace News Archive

OraSure Technologies, Inc., a global leader in point-of-care testing and sample collection technologies, announced that Chief Financial Officer Roberto Cuca has resigned from the Company effective September 17, 2021.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in two upcoming virtual investor conferences.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that management will be participating in the following upcoming investor conferences

Prelude Therapeutics Inc., a clinical-stage precision oncology company, announced that members of its management team will participate in two upcoming virtual investor conferences.

Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in two upcoming healthcare investor conferences.

Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye, announced a new Phase 1 grant award from the National Institute of Aging at the National Institutes of Health.

Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, announced that members of its senior management team will participate at the following investor conferences:

NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced that it will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 9th at 12:30 pm Eastern time.

Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that Dr Megan Baldwin, the Company’s Chief Executive Officer, will participate in the following investor conferences in September:

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced that management will participate in three upcoming virtual investor conferences.